Gilead Sciences 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Third-quarter base business sales were $8.2 billion, up 16% year over year and 8% sequentially, the highest year-over-year growth for the base business since 2015.
- Including Viclary, total product sales were $8.3 billion, up 13% year over year and 9% sequentially.
- HIV sales were $6.2 billion, up 18% year over year; Biktarvi sales were $4.1 billion, up 10%, and Biktarvi reached an all-time high US treatment market share of 53%.
- HIV prevention sales nearly doubled year over year; yes-to-go sales were $305 million, up 31% sequentially, while Discovi sales were $1 billion, up 49% year over year.
- Trodelvy sales were $506 million, up 42% year over year, and reached an approximately $2 billion annual run rate; Livelzy sales were $203 million, up 93% year over year.
- Cell therapy sales were $355 million, down 18% year over year, reflecting ongoing competitive headwinds.
- Non-GAAP product gross margin was 88%, compared with 86% in the third quarter of 2025; non-GAAP diluted EPS was $2.55, compared with $2.47 in the same period in 2025.
- The company returned approximately $1.4 billion to shareholders in the third quarter, including $370 million of share repurchases.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good afternoon, everyone, and welcome to Gilead's third quarter 2026 earnings conference call. My name is Rebecca and I will be today's host. In a moment, we will begin our prepared remarks, followed by our Q&A session. To ask a question, please press star one, and to withdraw your question, press star one again. Now, I will hand the call over to Jacquie Ross, Senior Vice President, Treasurer, and Head of Investor Relations.
Thank you, Rebecca. Just after market close today, we issued a press release with earnings results for the third quarter of 2026. The press release, slides, and supplementary data are available on the investors section of our website at gilead.com. The speakers on today's call will be our Chairman and Chief Executive Officer, Daniel O'Day, our Chief Commercial and Corporate Affairs Officer, Johanna Mercier, our Chief Medical Officer, Dietmar Berger, and our Chief Financial Officer, Andrew Dickinson. After that, we will open the call to Q&A, where the team will be joined by Cindy Perettie, the Executive Vice President of Kite. Let me remind you that we will be making forward-looking statements. Please refer to slide two regarding the risks and uncertainties relating to forward-looking statements that could cause actual results to differ materially. With that, I will turn the call over to Dan.
Thank you, Jackie, and thanks everyone for joining us on today's call. Gilead delivered an exceptional third quarter that highlights the strength, breadth, and durability of the business. Third quarter base business sales were up 16% year-over-year, Gilead's strongest growth in more than a decade, driven by BIKTARVY, DESCOVY, and Yeztugo in HIV, TRODELVY in metastatic breast cancer, and Livdelzi in PBC. At the same time, we continue to advance our diverse pipeline as we prepare for the next phase of launches. In HIV, we continue to lead across treatment and prevention. In the third quarter, HIV sales grew 18% year-over-year. BIKTARVY achieved an all-time high U.S. market share, and we had a modest initial contribution from Bixlenvo, which launched in August. HIV prevention sales nearly doubled year-over-year. As expected, Yeztugo has rapidly established itself as the leading long-acting injectable option for HIV prevention.
Yeztugo and DESCOVY for PrEP combined have 50% market share today and a $4 billion annual run rate. As Dietmar will cover later, we believe we have the most comprehensive and diverse HIV pipeline in the industry, as well as in Gilead's history. Across daily and long-acting dosing, we are advancing a portfolio that will deliver new options for many years to come. The most near-term example is ISL/LEN. We expect to file this year, and if approved, this would be the first once-weekly oral treatment regimen for virally suppressed people with HIV. In oncology, TRODELVY delivered another very strong quarter. Sales were up 42% year-over-year, and with growing demand across triple-negative and HR-positive, HER2 negative metastatic breast cancer, TRODELVY reached an approximately $2 billion annual run rate.
In the third quarter, we received European approval of TRODELVY in combination with pembro for first-line PD-L1-positive metastatic triple-negative breast cancer, extending TRODELVY's benefits to patients earlier in treatment. Beyond TRODELVY and metastatic breast cancer, we now have seven clinical-stage antibody drug conjugate programs in oncology. In cell therapy, we are approaching an important catalyst with the potential approval of anito-cel toward the end of the year. This would bring our total number of approvals to 4 in 2026 alone. In inflammation, our third strategic area of focus, we are advancing and expanding our broad and differentiated pipeline that we believe will establish a durable new growth area for the company. We recently shared promising 12-week data for emvistegrast in inflammatory bowel disease, and we expect to advance the program into phase III studies in ulcerative colitis in 2027.
Emvistegrast has the potential to be a backbone therapy for inflammatory bowel diseases as a monotherapy or in combination with other mechanisms, including the oral IL-23 receptor inhibitor we recently agreed to acquire. Beyond IBD, we have our IRAK4 inhibitor, for which we plan to share data at the upcoming ACR meeting, as well as gamgertamig, which represents a promising approach to B-cell-driven autoimmune diseases, with additional data expected later this year. Overall, our inflammation pipeline now includes 13 clinical programs, giving us multiple opportunities to deliver meaningful advances for patients. In summary, the third quarter continues what is proving to be a stellar year of execution and performance. This has enabled us to raise our 2026 base business revenue guidance by $1.6 billion over the course of the year while advancing a robust pipeline and preparing for the next wave of potential launches.
This fundamental strength in our business means we are well-placed to adapt to potential policy headwinds. As you know, BIKTARVY was selected for the maximum fair price determination process. That process is now complete, and CMS have informed us of the price they have set. As we have previously shared, this will have an impact on BIKTARVY revenues in 2028. Andy will share details in his section of the call. As this third quarter has reinforced, again, our strategy of diversification has reshaped our business and is expected to continue to drive sustainable growth. Looking forward, the multiple opportunities to drive growth across all three of our therapeutic areas, the strength and diversity of our pipeline within and beyond HIV, and a disciplined operating model all give us confidence in the trajectory of the company. With that, I will hand it over to Johanna.
Thanks, Dan, and good afternoon, everyone. Starting on slide 7, total product sales, excluding Veklury, of $8.2 billion were up 16% year-over-year, driven by strong HIV performance, TRODELVY, and Livdelzi. This is the highest year-over-year growth for our base business since 2015. Sequentially, sales were up 8%, driven by growth in HIV, TRODELVY, and Livdelzi. Including Veklury, third quarter total product sales were $8.3 billion, up 13% year-over-year and 9% sequentially. Moving to HIV on slide 8, third quarter HIV sales of $6.2 billion were up nearly $1 billion or 18% year-over-year and represented the highest year-over-year growth since the fourth quarter of 2018. This strong performance was driven by higher average realized price, higher demand, and favorable inventory dynamics. Sequentially, HIV sales were up 10%, primarily driven by higher inventory, demand, and average realized price. We expect these inventory dynamics to normalize by year-end.
Looking at HIV treatment in more detail on slide 9, BIKTARVY sales of $4.1 billion were up 10% year-over-year, driven by higher demand and average realized price, in addition to favorable inventory dynamics. Sequentially, BIKTARVY sales increased 8%, driven by favorable inventory dynamics and higher demand, partially offset by lower average realized price due to channel mix. BIKTARVY reached an all-time high treatment market share of 53% in the U.S., supported by continued gains among new patients, strong retention, and improving access following adjustments to the Florida ADAP program earlier in the year. While we have not yet seen the HIV treatment market return to its typical 2%-3% growth, we have seen signs of stabilization.
BIKTARVY has also demonstrated continued resilience amid changes related to the Affordable Care Act, reflecting the strength of the product profile and of our commercial teams to help people living with HIV maintain access to treatment. Bixlenvo, our new daily oral combination of bictegravir and lenacapavir for virally suppressed adults with HIV, was launched late into the third quarter following U.S. approval in August. While it is still early days for the launch, we are pleased with the uptake we are seeing in virally suppressed people on complex regimens, which has been in line with our expectations. Overall, we remain focused on expanding coverage and bringing this new option for people who want to switch or simplify their HIV treatment. Moving to HIV prevention or PrEP on Slide 10, sales nearly doubled year-over-year in the third quarter, once again outpacing overall U.S. PrEP market growth of 14% year-over-year.
This is a clear testament to Gilead's strong commercial execution. Building on our leadership, now with 50% PrEP market share, our innovative portfolio has accounted for the vast majority of market growth since 2025. Additionally, demand in the long-acting injectable market doubled year-over-year, and we are pleased to share Yeztugo is now the leading injectable prevention regimen, with sales of $305 million, up 31% sequentially, and on track to deliver full-year sales of approximately $1 billion. Importantly, we continue to see that more than 70% of users have returned for their second injection, resulting in combined protection of up to a full year. This continues to reinforce Yeztugo's best in PrEP persistency profile, as defined by patients returning for their re-injections after six months.
We are particularly encouraged by the mix of new starts, with the majority continuing to come from individuals switching from other PrEP regimens, while the share of PrEP-naive individuals increased during the quarter. Looking ahead, we believe the potential launch of once-weekly oral Yeztugo could further expand choice and support continued growth by reaching additional individuals who could benefit from PrEP. Looking at DESCOVY, total sales of $1 billion were up 49% year-over-year, driven by higher average realized price and favorable inventory dynamics. PrEP sales continue to account for approximately 80% of total DESCOVY sales. Sequentially, total DESCOVY sales were up 8%, driven by higher than usual inventory build and higher demand. In just three quarters, DESCOVY sales have already exceeded that of full year 2025, driven primarily by strong demand and pricing favorability.
Moving to Livdelzy on slide 11, sales of $203 million were up 93% year-over-year and 21% sequentially, driven by increased demand in both the U.S. and Europe. Livdelzy is the market leader in the U.S. and is helping to drive expansion of the second-line PBC market. Looking ahead, we are excited to share the detailed results from Livdelzy's Phase III IDEAL study at the upcoming AASLD Liver Meeting. The study evaluated Livdelzy in PBC patients with ALP between 1 and 1.67 times the upper limit of normal, which account for approximately half of the second-line-eligible population and remain associated with an increased risk of disease progression. We are working towards global filings to update Livdelzy's label to include data from the IDEAL study and expect a U.S. label update in 2027.
Together with sales in our viral hepatitis portfolio, liver disease sales were at $927 million, up 13% year-over-year, reflecting increased demand for Livdelzy in PBC, as well as favorable pricing dynamics for HCV and HBV, partially offset by lower HCV starts. Sequentially, sales were up 6%, reflecting higher average realized price and inventory dynamics, partially offset by lower demand for HCV products. Moving to slide 12. Trodelvy sales of $506 million for the quarter, now a $2 billion annual run rate, was up 42% year-over-year and 11% sequentially, driven by strong demand growth in both metastatic triple-negative and HR-positive, HER2-negative breast cancer across the U.S. and Europe. Following the first-line approvals in the U.S. and Europe earlier this year, Trodelvy is establishing itself as the backbone of treatment in metastatic triple-negative breast cancer, and we are working to expand Trodelvy's first-line opportunity further into new markets.
Triple-negative breast cancer remains one of the most aggressive and challenging forms of breast cancer to treat. Bringing Trodelvy into the first-line setting represents an important opportunity to reach significantly more patients earlier in their treatment journey, when the potential impact of treatment may be the greatest. We are incredibly pleased with the first-line metastatic TNBC uptake thus far. Moving to slide 13, and on behalf of Cindy and the Kite team, third quarter cell therapy sales of $355 million were down 18% year-over-year, reflecting ongoing competitive headwinds. Looking ahead, we are also focused on the next potential chapter of growth for our cell therapy business. Our launch preparations are in full force as we approach anito-cel's December 23 PDUFA date in fourth-line plus relapsed or refractory multiple myeloma.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
18 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
